Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
Tumor Immunotherapy01:27

Tumor Immunotherapy

1.7K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.7K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Cancer Therapies02:49

Cancer Therapies

9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K
Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.5K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.5K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.6K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Durable Response to Sotorasib Plus Panitumumab in NRAS G12C-Mutated, Microsatellite Instability-High (MSI-H) Rectal Cancer Refractory to Immunotherapy.

Cureus·2026
Same author

Real-World Outcomes and Progression Patterns with First-Line Osimertinib in Patients with Advanced <i>EGFR</i>-Mutant Non-Small Cell Lung Cancer: A Nationwide Turkish Oncology Group Study.

Cancers·2026
Same author

Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort-A Turkish Oncology Group (TOG) Study.

Medicina (Kaunas, Lithuania)·2026
Same author

Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study.

Current oncology (Toronto, Ont.)·2026
Same author

Epidemiology and Clinical Profiles of <i>Bacteroides fragilis</i> Bacteremia in a Tertiary Care Setting: A 5-Year Review.

The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale·2026
Same author

A phase I study evaluating subcutaneous administration of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced solid malignancies.

Cancer immunology, immunotherapy : CII·2026

Related Experiment Video

Updated: Jan 14, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K

Cell therapy in sarcoma: current landscape and future directions.

Taha Koray Sahin1, Theodora Germetaki2, Deniz Can Guven1

  • 1Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.

Journal for Immunotherapy of Cancer
|January 12, 2026
PubMed
Summary

Cell therapies show promise for treating rare sarcomas, offering durable responses. Challenges include identifying specific targets and overcoming the tumor microenvironment for broader application.

Keywords:
Adoptive cell therapy - ACTChimeric antigen receptor - CARImmunotherapyT cell Receptor - TCRTumor infiltrating lymphocyte - TIL

More Related Videos

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.4K

Related Experiment Videos

Last Updated: Jan 14, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

14.9K
Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas
09:21

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

7.6K
Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts
07:18

Isolation and Characterization of Tumor-initiating Cells from Sarcoma Patient-derived Xenografts

Published on: June 13, 2019

7.4K

Area of Science:

  • Oncology
  • Immunotherapy
  • Cellular Therapy

Background:

  • Sarcomas are rare, heterogeneous mesenchymal tumors with limited response to conventional treatments.
  • Immune checkpoint inhibitors show minimal efficacy in many sarcoma subtypes.
  • Cell therapy, particularly T-cell receptor T-cell (TCR-T) therapy, is emerging as a viable treatment strategy.

Purpose of the Study:

  • To review the current landscape and future potential of various cell therapies in treating sarcomas.
  • To highlight recent advancements and approvals in sarcoma cell therapy.
  • To identify challenges hindering the widespread application of cell therapies in sarcomas.

Main Methods:

  • Review of current literature on cell therapies for sarcomas.
  • Analysis of different cell therapy modalities including TCR-T, CAR-T, TILs, NK cells, and MSCs.
  • Discussion of biological and clinical barriers to effective sarcoma cell therapy.

Main Results:

  • Genetically-engineered TCR-T therapies targeting MAGE-A4 have shown durable responses in synovial sarcoma.
  • Afamitresgene autoleucel (TCR-T) approval marks a significant step for cell therapy in solid tumors.
  • Multiple cell therapy types are being explored for sarcoma treatment.

Conclusions:

  • Cell therapies offer a promising avenue for sarcoma treatment, with recent approvals demonstrating potential.
  • Overcoming challenges like lack of specific targets, tumor heterogeneity, and immunosuppressive microenvironment is crucial.
  • Further research and careful evaluation of clinical feasibility, logistics, and cost-effectiveness are needed for successful implementation.